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The successful ex vivo expansion of a large numbers of T cells is a prerequisite for adoptive immunotherapy. In this study, we
found that cell density had important effects on the process of expansion of T cells in vitro. Resting T cells were activated to
expand at high cell density but failed to be activated at low cell density. Activated T cells (ATCs) expanded rapidly at high cell
density but underwent apoptosis at low cell density. Our studies indicated that low-cell-density related ATC death is mediated
by oxidative stress. Antioxidants N-acetylcysteine, catalase, and albumin suppressed elevated reactive oxygen species (ROS) levels
in low-density cultures and protected ATCs from apoptosis. The viability of ATCs at low density was preserved by conditioned
medium from high-density cultures of ATCs in which the autocrine survival factor was identified as catalase. We also found
that costimulatory signal CD28 increases T cell activation at lower cell density, paralleled by an increase in catalase secretion.
Our findings highlight the importance of cell density in T cell activation, proliferation, survival and apoptosis and support the
importance of maintaining T cells at high density for their successful expansion in vitro.
1. Introduction
T cells are a critical component of the cellular immune
response. In the past two decades, adoptive transfer of
tumor reactive T cells into cancer patients has been created
as an immunotherapy method to combat cancer [1]. This
includes the early studies with lymphokine-activated killer
(LAK) cells derived from ex vivo amplification of autologous
lymphocytes with interleukin-2 (IL-2), late studies with
tumor infiltrating lymphocytes (TILs) isolated from tumor
specimens, and recent studies with genetically modified
tumor reactive T cells [2]. The prerequisite for the success
of adoptive immunotherapy relies on the successful ex vivo
expansion of a large amount of T cells (up to 1011).
The ex vivo expansion of T cells for adoptive
immunotherapy usually involves two phases. The first phase
is T cell activation, in which resting T cells are activated
with anti-CD3 antibody or plus anti-CD28 antibody
supplemented with IL-2. The second phase is activated T cell
(ATC) proliferation. After activation, resting T cells become
ATCs and undergo vigorous cell proliferation for about two
to three weeks and the ATCs lose their proliferation capacity
in about four weeks. Maintaining high cell density has been
considered important among investigators performing ex
vivo T cell expansions for clinical therapeutic applications.
This report addresses formally the basis for this observation.
Cell density has been reported to be an important factor
in maintaining certain T and B cells in vitro. Resting T
cells die rapidly by apoptosis when cultured under diluted
conditions but survive for extended periods when cultured
at high cell density [3]. This effect was found to be mediated
by soluble factors and independent of integrin-mediated
signals. An acute T-lymphocytic leukemia cell line, CCRF-
CEM, was reported to display a cell density-dependent
growth characteristic [4]. CEM cells grow well at cell density
>2 × 105 cells per mL, but at low cell densities the
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cultures rapidly undergo apoptosis. The viability of low-
density CEM cells could be preserved by supplementing with
“conditioned” medium from high-density CEM cultures.
Catalase was identified as the active component in the
conditioned medium. B cell chronic lymphocytic leukemia
(CLL) was reported to be dependent on cell density for
surviving in cultures [5]. CLL cells survival was strongly
enhanced at high cell density. Conditioned medium from
high cell density CLL cells produced a marked increase in the
viability of low cell density autologous cells. Again, autocrine
catalase was identified as the survival factor in the high cell
density cultures.
Reactive oxygen species (ROS) have been shown to
contribute to the death of CEM cells and CLL cells at low cell
density [4, 5]. ROS are highly reactive metabolites that are
generated during normal cell metabolism. Intracellular ROS
derive mainly from leakage of electrons from mitochondrial
electron transport chains that reduce molecular oxygen
to superoxide ions. Cells possess antioxidant systems to
control their redox state, to reduce oxidative stress and to
maintain cell survival [6]. Superoxide ions are converted
to hydrogen peroxide (H2O2) by the action of Cu2+/Zn2+-
dependent or Mn2+-dependent superoxide dismutases, and
H2O2 is then detoxified by catalase or glutathione perox-
idase. H2O2 can also react in vivo to generate the highly
damaging hydroxyl radical by the Fe2+-dependent Fenton
reaction or the Fe2+-catalyzed Haber-Weiss reaction [6, 7].
At subtoxic levels, ROS may play an essential signaling
role in cell growth and differentiation [8–11]. At elevated
levels, however, intracellular ROS are sufficient to trigger
cell death [12–16]. Antioxidants that limit ROS-induced
cell damage can suppress apoptosis in many systems. For
example, N-acetylcysteine (NAC), which elevates intracellu-
lar glutathione levels, delays activation-induced cell death of
a T cell hybridoma [17]. NAC or the iron chelator pyrrolidine
dithiocarbamate (PDTC) or enforced expression of Mn2+-
dependent superoxide dismutase inhibits apoptosis induced
by TNF-α which can stimulate ROS production [18–21].
Similarly, cell death through oxidative mechanisms has been
shown to be opposed by protein albumin at physiologic
concentrations directly by scavenging for free oxygen radicals
through the free cysteinyl sulfhydryl moiety and indirectly by
maintaining the reduced state of cellular proteins [22–24].
ROS have also been shown to be the decisive contributors
to the death of activated T cells (ATCs) [25–28]. First, the
ATCs have increased levels of ROS [25, 26, 29–31]. Second,
ATC death is prevented by manganese (III) tetrakis (5, 10, 15,
20-benzoic acid) porphyrin (MnTBAP), an antioxidant that
has been shown to inhibit ROS-induced death in different
types of cells [25]. Evidence shows that ROS lead to ATC
death by at least two pathways, one mediated by caspase
activation and subsequent proteolytic cellular disintegration
and the other driven by ROS themselves [25].
While cell density has been found to be important for the
survival of resting T cell and certain but not all leukemic T
and B lines, it remains unclear if normal T cells behave in a
cell density-dependent manner during T cell expansion. In
this study, we confirm a critical role of cell density in resting
T cell activation and ATC expansion. We found that resting
T cells need to be kept at high cell density for optimized
activation and ATCs need to be kept at high cell density
for optimized expansion. We show that the cell density-
related ATC apoptosis is triggered by oxidative stress that is
in turn opposed by the secretion of an autocrine survival
factor, mainly catalase: at high cell density, more catalase
accumulates in the medium and opposes the oxidative
apoptosis. Further, we confirm the antioxidant activity of
added NAC or of serum albumin at high concentrations
that protects ATCs from apoptosis when cultured at low cell
density.
2. Materials and Methods
2.1. Reagents. N-acetylcysteine (NAC), catalase, and 3′-
amino-1,2,4-triazole (ATZ) were purchased from Sigma
Chemical (St Louis, MO, USA). Human serum albumin was
from Bayer Corporation (Elkhart, IN, USA).
2.2. Cell Purification, Activation, and Culture. Peripheral
blood mononuclear cells (PBMCs) were isolated from
venous blood from healthy adults by centrifugation over
Histopaque-1083 (Sigma). For resting T cells activation
study, PBMCs were cultured in 6-well plates in different
cell densities and were activated in serum-free AIM V
media (Gibco, Gaithersburg, MD, USA) supplemented with
100 U/ml IL-2, 100 ng/mL mouse antihuman CD3 anti-
body OKT3 (Ortho Biotech, Raritan, NJ, USA) only or
with the addition of 100 ng/mL mouse antihuman CD28
antibody mAb9.3 (gift from Dr. Carl H. June, University
of Pennsylvania, Philadelphia, PA, USA). For preparation
of ATCs, PBMCs were activated at 1 × 106/mL cells in
serum-free AIM V media supplemented with 100 U/ml IL-2,
100 ng/mL OKT3 in 75 cm2 flasks for 3 days. ATCs were then
washed and cultured in the AIM V medium supplemented
with 100 U/mL IL-2 for an additional 7 days before use in
experiments.
2.3. Monitor of T Cell Activation and Cell Division. Accom-
panied with T cell activation, there is a significant cell size
enlargement from resting T cells to ATCs, with cytokines
such as IL-2 and IFN-γ production and surface molecules
such as CD69 and CD25 expression. ATCs can be distin-
guished from resting T cells and other types of PBMCs
as the enlargement in forward-angle light scatter (FS) by
flow cytometric analysis and it is identical with CD69 or
CD25 staining. T cell activation was monitored by counting
the percent of ATCs in the culture by flow cytometer
and confirmed with microscope. To monitor cell division,
ATCs were labeled with 1 μM carboxy-fluorescein diacetate
succinimidyl diester (CFSE) (Molecular Probes, Eugene, OR,
USA) [32] and cultured for 6 days. Cells were harvested and
cell division was analyzed by the dilution of CFSE in the
daughter cells by flow cytometer.
2.4. Detection of Apoptosis. ATC apoptosis was determined
by cell shrinkage and DNA cleavage. Cell viability of ATCs
was analyzed by flow cytometry [5, 33, 34]. Cell shrinkage
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accompanying ATC apoptosis was detected as a reduction in
forward-angle light scatter (FS) by flow cytometric analysis.
Agarose gel electrophoresis was used to detect internucleoso-
mal cleavage fragments of DNA following apoptosis [4, 35].
2 × 106 cells were pelleted and resuspended in 500 μL of
ice-cold lysis buffer (20 mM Tris·HCl, 10 mM EDTA, and
0.2% Triton X-100, pH 7.4). Proteinase K was added at
100 μg/mL and incubated at 50◦C overnight, followed by
further incubation at 37◦C for 2 hours with the addition
of RNase. DNA was extracted twice with phenol/chloroform
at 1 : 1 and precipitated with isopropanol. The DNA was
electrophoresed through a 1% agarose gel and stained with
ethidium bromide.
2.5. Measurement of Intracellular Oxidative Stress. Cells were
gently resuspended in 10 μM dihydrorhodamine 123 (DHR)
(Molecular Probes) and incubated for 30 minutes and then
analyzed by flow cytometry [5, 7]. The level of intracellular
ROS was inferred from the mean fluorescence intensity
(MFI) of DHR-stained cells. Dead cells and debris were
excluded from analysis by electronic gating of forward and
side scatter measurements.
2.6. Generation of Conditioned Medium. Cells were cultured
at 1 × 106/mL (ATCs) or confluent (MIP101 cells, a human
colon carcinoma cell line) in 75 cm2 flasks. After 2 days in
culture, the conditioned medium (CM) was removed from
the culture flasks and centrifuged at 1500 rpm for 10 minutes.
The CM was then passed through a sterile 0.45 μm filter.
2.7. Detection of Catalase. Detection of catalase was per-
formed by western blot and dot blot. For western blot,
control medium, ATCs CM, and cell lysates from ATCs
were run on 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) gels and electrotransferred
to nitrocellulose membranes. For dot blot, 100 μL culture
medium from untreated, anti-CD3 activated and anti-CD3
plus anti-CD28 activated PBMCs were blotted on to nitro-
cellulose membrane by using a dot blot apparatus (Bio-Rad,
Hercules, CA, USA). The membranes were blocked with 5%
nonfat dry milk in Tris-buffered saline (20 mM Tris/500 mM
NaCl, pH 7.5) for 1-2 hours. Membranes were washed with
TTBS (0.05% Tween-20 in Tris-buffered saline), and mouse
antihuman catalase mAb antibody (Sigma) was added at
a dilution of 1 : 1000 for 1 hour, followed by incubation
with HRP-conjugated goat antimouse IgG antibody at a
dilution of 1 : 1000 for 1 hour, all in 1% non-fat dry milk
in TTBS. The membrane was developed with enhanced
chemiluminescence reagent (Amersham, England, UK) and
exposed to X-ray film for 5–60 seconds.
2.8. Detection of Intracellular Albumin. Analysis of intra-
cellular albumin was performed using immunofluorescence
and flow cytometry. Cells were fixed and permeabilized with
a Fix & Perm kit (Caltag Laboratories, Burlingame, CA, USA)
and then stained with mouse antihuman albumin (Sigma),
followed by staining with a secondary goat antimouse FITC-
conjugated antibody (Caltag Laboratories).
3. Results
The objective of this study was to determine the role of cell
density in ex vivo expansion of T cells. To mimic the actual
situation in preparation for clinical applications, resting T
cells were not further purified from the bulk PBMCs in
the experiments. Typically, PBMC are composed of 50–
70% T cells, and smaller numbers of B cells, NK cells, and
monocytes.
3.1. Cell Density Determines the Fate of T Cells Activation.
Efficient activation of resting T cells requires signal 1 (TCR,
CD3) and signal 2 (CD28) costimulation [36]. Activation of
T cells through soluble OKT3 (anti-CD3) antibody depends
on crosslinking of the antibody through Fc receptor on
monocytes present in PBMCs preparations that also provide
costimulation through B7 to CD28 on the T cells [37].
Typically, PBMCs cell concentrations of at least 1 × 106/mL
are specified for this T cell activation. At lower cell densities,
the opportunities for cell-cell contact are diminished and
activation is incomplete or absent.
This is confirmed in our results. Following activation
with OKT3 and IL-2 at 1 × 106 cells/mL for 6 days, 61% of
cells in the culture showed a T blastic morphology by flow
cytometry versus 23%, 9%, and 8% for the lower PBMCs
densities of 1 × 105, 1 × 104 and 1 × 103/mL, respectively
(Figure 1). At an intermediate T cell density of 1 × 105/mL,
addition of an agonist anti-CD28 antibody that bypasses
need for B7 on monocytes partially compensates for the
reduced cell contacts, doubling the activated fraction from
23% to 47%. At the lowest cell densities, this maneuver was
not effective and at the highest it was unnecessary, where
the activated phenotype was maximal with OKT3 alone. At
higher density, there are more chances of cell contacts and
B7-CD28 interactions, and costimulation is maximal with-
out added anti-CD28 antibody. Such maximally activated T
cells (ATC) were applied throughout this study.
As analyzed by flow cytometry from one typical exper-
iment, the PBMCs isolated from normal human blood
were 57.2% CD3+, 38.8% CD4+, 21.6% CD8+, 0.37%
CD4+CD8+, 39.2% CD4−CD8−, 49.8% CD28+, 53.6%
CD2+, and 60.6% CD11a+. After 3 days activation with
OKT3 and expansion for 7 days (total 10 days), the cell
populations were 99.7% CD3+, 81.7% CD4+, 15.6% CD8+,
1.9% CD4+CD8+, 0.76% CD4−CD8−, 99.4% CD28+,
99.5% CD2+, and 100% CD11a+. Such 10-day cultures were
used in the ATC studies that follow.
3.2. ATCs Proliferate at High Cell Density. To examine the
relation between cell density and ATC proliferation, T cells
were activated under high density conditions as in Section 3.1
and then reseeded at varying cell densities and monitored
over time for viable cell numbers. There was a progressive
increase in the number of viable cells when ATCs were
cultured at 1 × 105/mL, but a progressive decline in viable
cells when ATCs were cultured at 1×104/mL. After 6 days, the
number of viable ATCs increased 340% when cultured at 1×
105/mL but decreased by 75% when cultured at 1 × 104/mL
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Figure 1: Cell density determines the fate of T cell activation.
PBMCs cultured at different cell densities in 6-well plates were
activated with anti-CD3 antibody alone or plus anti-CD28 antibody
in the presence of IL-2. T cell activation was measured as percentage
of activated T cells in culture after six days of activation by
morphological criteria of T cell blasts on flow cytometer. Similar
results were obtained in two independent experiments.
(Figure 2(a)). Furthermore, when measuring dividing cells
by CFSE, 68% of ATCs underwent division when cultured at
1× 105/mL, 35% at 1× 104/mL, and only 15% at 1× 103/mL
(Figure 2(b)). These results establish a correlation between
cell density and ATC expansion in vitro.
3.3. ATCs Undergo Apoptosis at Low Cell Density. To examine
the relation between cell density and cell viability, ATCs
cultured at different cell densities were evaluated after
24 hours. A condensed cell size by morphology on flow
cytometry has been shown to correlate with apoptosis/cell
death markers under experimental conditions close to our
own [5, 33, 34] and was used to distinguish apoptotic from
viable cells in our tests. At cell density of 1 × 105/mL, viable
cells remained unchanged at 92% after 24 hours but declined
to 62% and 34% when ATCs were cultured at 5 × 104/mL
and 1 × 104/mL over the same time interval (Figure 3(a)).
Increasing IL-2 100-fold from 100 IU/mL to 10,000 IU/mL
did not rescue ATCs from death at low cell density (data not
shown).
To determine by another measure whether ATCs died
by apoptosis when cultured at low cell density, a DNA
fragmentation assay was employed. Apoptosis is a distinctive
form of cell death that occurs in a wide range of physiological
and pathological situations [38]. It differs fundamentally
from degenerative cell death or necrosis and was originally
defined by the orderly sequence of ultrastructural changes
that accompanies cell elimination during development [39].
Biochemically, it is best characterized by the presence of
internucleosomal cleavage of DNA into 180–200 base-pair
fragments [39, 40], which can be demonstrated by gel elec-
trophoresis. As shown in Figure 3(b), DNA was fragmented
when ATCs were cultured at low cell density (1×104/mL) but
remained intact at high cell density (1×106/mL), confirming
that apoptosis is the mechanism of ATC death at low cell
density.
3.4. ROS Are the Mediators of ATC Apoptosis at Low Cell
Density. Elevated intracellular ROS can trigger cell death
[12–16]. We hypothesized that ROS were the mediators of
ATC apoptosis at low cell density. To test this hypothesis, we
measured the levels of intracellular ROS in ATCs cultured at
different cell densities and tested if antioxidants can block
ATC apoptosis at low cell density.
ROS include superoxide and hydroxyl-free radicals and
H2O2. To measure intracellular ROS, we used the oxidation-
sensitive fluorescent probe DHR [7]. DHR is nonfluorescent,
uncharged, and accumulates within cells, whereas R123,
the product of intracellular DHR oxidation, is fluorescent,
positively charged, and trapped within cells [41]. ATCs
cultured at high cell density (1×105/mL) and low cell density
(1 × 104/mL) for 24 hours were incubated with DHR, and
R123 fluorescence was measured by flow cytometry. The rate
of DHR oxidation was significantly greater in ATCs cultured
at low cell density than in ATCs cultured at high cell density
(Figure 4(a)), confirming a correlation of intracellular ROS
with apoptosis.
Antioxidants inhibit ROS-mediated apoptosis in many
systems by limiting ROS-induced cell damage [16]. We there-
fore tested the effects of three antioxidants on ATC apoptosis
at low cell density. NAC elevates intracellular glutathione
[17] that is a substrate for glutathione peroxidase to catalyze
the breakdown of H2O2; catalase detoxifies H2O2 produced
by superoxide ions [7]; and albumin can directly scavenge
reactive oxygen species through its free cysteinyl—SH [42].
ATCs were cultured at low cell density (1 × 104/mL) in the
presence of antioxidants at different concentrations for 24
hours. Cell viability and intracellular ROS were measured by
flow cytometry. All agents significantly protected cells from
death in a dose-dependent manner. In general, the increased
survival was paralleled by a reduction in intracellular ROS
levels with higher levels of the antioxidants (Figure 4(b)).
This further supports the hypothesis of ROS as a mediator
of apoptosis in ATCs cultured at low cell density.
Albumin is the most abundant plasma protein and
has been suggested to constitute an important extracellular
antioxidant [43, 44]. Interestingly, the reduction in ROS with
albumin appeared somewhat less than predicted versus the
survival benefit observed (Figure 4(b)), suggesting that there
may be additional, downstream means by which albumin
may mitigate the harmful effects of ROS. A further feature
of interest was the demonstration of increased albumin
endocytosis in the low density ATCs versus those grown at
high density (Figure 4(c)). Whether this was a generalized
effect on endocytosis or selectively related to albumin was not
Journal of Biomedicine and Biotechnology 5
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Figure 2: ATCs proliferate at high cell density. ATCs were activated at high density and then reseeded in fresh growth medium plus IL-2
at varying concentrations. (a) Numbers of ATCs at different cell densities. ATCs were cultured at high cell density (1 × 105/mL) or low cell
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for 6 days. Cell division was monitored by CFSE dilution in the dividing cells as analyzed by flow cytometry.
examined. It was also not discriminated whether it was the
internalized albumin or the external protein that mediated
the survival benefits; its mechanism of action was not further
investigated.
3.5. Soluble Factor Secreted by ATCs at High Cell Den-
sity Prevents Apoptosis of ATCs at Low Cell Density. The
protective effect of high cell density indicated that either
cell-to-cell contacts or soluble factor(s) produced by ATCs
were inhibiting ATC apoptosis under this condition. To
assess whether soluble factor(s) were involved, conditioned
medium from ATCs cultured at high cell density (1 ×
106/mL) was collected and added to ATCs cultured at
low cell density (1 × 104/mL). With increased fractions of
conditioned medium in the total medium, the intracellular
ROS levels decreased in ATCs cultured at low cell density and
their viability increased (Figure 5(a)). These data confirmed
the secretion of one or more soluble factors at high cell
density that functioned as antioxidant to protect ATCs from
apoptosis.
A similar protective effect was observed with conditioned
medium from a human colon carcinoma cell line, MIP101
(Figure 5(b)) and from a human T cell leukemia cell line
(data not shown). These results indicate that the protective
soluble factor(s) secreted by ATCs at high cell density are
not ATC-specific. This result is compatible with the potential
of diverse cell lines to function as feeder cells during T cell
cloning procedures [40].
3.6. Autocrine Catalase Protects ATCs from Apoptosis. Based
on prior studies of cytoprotective effects of catalase in
cultures of lymphoid leukemia cells [5, 40], we hypothesized
that the cell density effect on ATC survival was also mediated
by secreted catalase. To determine whether catalase was one
of the autocrine survival factors, western blot was performed
(Figure 6(a)). The enzyme was clearly detected in cell lysates
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bromide. 100 bp DNA ladder markers were included as markers (M).
and conditioned medium, but not in control medium. In two
separate assays, catalase in CM (e.g., lane 2) was estimated
at 2.5–5 μg/mL (6–12 units/mL) in comparison with control
purified catalase. Estimates from cell lysate (lane 3) are 2 μg
per 106 cells. This means that in 24 hours 106 cells secrete
into 1 mL of medium, a quantity (2.5–5 μg) that equals or
exceeds what is present in the cells themselves. Further, this
concentration of catalase in CM corresponds closely with
levels that give maximum benefit to ROS control and cell
viability in Figure 4(b) (e.g., ∼10 units/mL).
We next sought to establish whether catalase contributed
to the survival-enhancing effect of the conditioned medium.
To address this question, the effect of the selective catalase
inhibitor, 3′-amino-1,2,4-triazole (ATZ) [5, 45–48] was
examined. ATZ significantly blocked the survival-enhancing
activity of the conditioned medium (Figure 6(b)), indicating
that catalase plays the major role in this cytoprotective effect.
3.7. Elevated Autocrine Catalase Accumulation in CD28
Costimulated T Cell Activation. Having established the role
of autocrine catalase as a cell survival factor in ATC pro-
liferation, an interesting question arises: whether autocrine
catalase also plays a role in CD28 costimulated T cell
activation. An intermediate cell concentration was shown
in Figure 1 to benefit from CD28 costimulation, PBMCs
at 1 × 105/mL were activated with anti-CD3 antibody
without or with anti-CD28 antibody in the presence of
IL-2. Compared with anti-CD3 antibody activation alone,
there was a significant more amount of autocrine catalase
accumulation in the anti-CD28 antibody costimulated cell
cultures (Figure 7). These results indicate that the improved
T cell activation at lower cell density with CD28 is paralleled
by an enhanced autocrine catalase secretion.
4. Discussion
Cell density has been reported to be important for cell
survival in cultures of resting T cells [3] and certain leukemic
T and B cell lines [4] but not reported in other leukemic
T cell lines such as Jurkat and H9 T cells [5]. Although
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there are frequent communications between investigators
performing ex vivo T cell expansions for clinical therapeutic
applications that maintaining high cell density is an impor-
tant consideration factor in T cell expansion, the relation
between cell density and T cell expansion remains unclear. In
this study, we systematically examined the relation between
cell density and normal human T cell expansion in vitro,
providing evidence for optimizing T cell expansion protocols
for clinical applications. From our results, PBMCs have to be
seeded at high cell density (≥1 × 106/mL) for optimal T cell
activation. The addition of CD28 costimulation helps resting
T cells to be activated at lower cell density and coordinately
yields elevated catalase secretion and accumulation in the
cultures. Maintaining high cell density is also important for
ATC proliferation. ATCs undergo apoptosis when cultured
at cell density of 1× 104/mL or less. Our mechanistic studies
support the role of ROS and oxidative stress apoptosis in ATC
death at low density. At high cell density, the extracellular
accumulation of secreted catalase reduces intracellular ROS
species and alleviates their toxic effects.
4.1. Cell Density Plays a Critical Role in Ex Vivo Expansion
of T Cells. Current protocols for ex vivo expansion of T
cells for clinical adoptive immunotherapy usually involve the
activation of PBMCs with OKT3 alone or plus anti-CD28
antibody in the presence of IL-2. When expanding T cells in
vitro, our results indicate that it is critical to maintain the
cells at high cell density during both T cell activation and
ATC expansion phases. It is reported that OKT3 has to be
immobilized on plastic or crosslinked via accessory cells in
PBMCs through Fc receptor binding for the activation of
T cells [37]. At low cell density, where the cell-cell contact
is poor, the OKT3 may not be efficiently crosslinked to
activate resting T cells. We also found that the addition
of costimulation through anti-CD28 antibody improves the
activation of resting T cells at lower cell density. Unlike the
OKT3, the soluble form of mAb9.3 can induce costimulation
directly without the need for crosslinking [37]. Interestingly,
there is a correlation between CD28 costimulation and
elevated catalase accumulation in the cultures. At present,
there is no basis on which to infer whether catalase is in
the CD28 pathway or merely one of the many downstream
components of T cell activation. Once being activated, the
ATCs have to be kept at high cell density for survival and
efficient proliferation.
When T cells are activated, T cells secrete abundant
cytokines such as IL-2 and other growth factors for cell
proliferation and survival. Maintaining high cell density
in culture may enable the accumulation of such autocrine
products to reach a relatively high concentration to support
the proliferation and survival of ATCs. It is interesting to
notice that under physiological conditions, T cell immune
responses can only be exclusively induced in organized
lymphoid tissues but not elsewhere in the body [49–53].
Naı¨ve T cells traffic constitutively through secondary lym-
phoid organs where they encounter antigen-loaded dendritic
cells and are activated to proliferate and differentiate into
activated effector T cells. Following this, effector T cells
then migrate to peripheral tissues to perform their function
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Figure 5: Soluble factors secreted by ATCs at high cell density
prevent apoptosis of ATCs at low cell density. ATCs cultured at
1 × 104/mL in 75 cm2 flasks were supplemented with conditioned
medium from (a) ATCs at high cell density or (b) MIP101 cells in
different concentrations for 24 hours. Cell viability and intracellular
ROS levels were analyzed by flow cytometry. Similar results were
obtained in two independent experiments.
[54]. Is it true that at locations such as the T cell areas of
secondary lymphoid organs, high cell density enables the
initiation of T cell responses with supported T cell survival
and proliferation, whereas at sites of peripheral tissues, low
cell density prevents T cell proliferation and minimizes
immunopathology? The question remains to be answered.
4.2. ROS Are the Mediators of ATC Apoptosis at Low Cell
Density. To understand why T cells have to be maintained
at high cell density for optimal expansion, it is important
to know why the T cells die at low cell density. ROS
such as superoxide and hydroxyl radicals and H2O2 are
continuously produced by cells, and their levels are regulated
by a number of enzymes and physiological antioxidants.
Excessive generation of ROS or failure to suppress elevated
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Figure 6: Autocrine catalase is the conditioned medium product
that protects ATCs from apoptosis. (a) Expression and secretion
of catalase by ATCs. Western blot of control medium (lane 1),
conditioned medium from ATCs (lane 2), cell lysates of ATCs
(lane 3), and catalase control (lane 4) probed with anticatalase
antibody. (b) Catalase inhibitor ATZ abrogates the protective effect
of conditioned medium from ATCs. ATCs were cultured at high
cell density (1 × 105/mL) (HD) or low cell density (1 × 104/mL)
(LD) in 75 cm2 flasks in the presence or absence of 50% conditioned
medium from ATCs (CM) and ATZ in 1 or 10 mM for 24 hours. Cell
viability was analyzed by flow cytometry.
intracellular ROS by the cellular regulatory systems has been
associated with cell death [12–15].
Differential effects of ROS on cell death are observed
depending on the level of ROS within the cell [26, 55]. High
levels of ROS lead to lipid peroxidation, damage to cellular
membranes, inactivation of caspase enzymes, and necrotic
cell death. Low levels of ROS can activate protein kinases
and phosphatases, mobilize Ca2+ stores, activate or inactivate
transcription factors, and lead to apoptotic cell death. ATCs
have been shown to have increased levels of ROS [25, 26, 29–
31] and ROS have been shown to be one of the decisive
contributors to the death of ATCs [25–28].
ROS are intermediates in the induction of FasL after
TCR engagement during activation induced cell death [25].
ROS-driven Bcl-2 downregulation is a necessary signal for
activated T cell autonomous death [25]. Besides, ROS may
affect many other molecules, such as membrane lipids,
transcriptional factors, and signal transduction proteins that
are involved in T cell apoptosis [25].
Our data demonstrate that ATCs cultured at low cell
density have higher levels of ROS than ATCs cultured at high
cell density and that reversal of high ROS in culture improves
T cell proliferative response and survival, implying that ATC
apoptosis at low cell density is triggered by ROS.
4.3. Antioxidants Promote ATC Survival at Low Cell Density.
Glutathione (GSH) is the major intracellular redox buffer
and plays an essential role in protecting cells against oxidative
damage [56]. In addition, changes in the intracellular GSH
levels modulate the expression of several genes involved in
the control of cell growth and differentiation [57, 58]. In T
lymphocytes, intracellular GSH is critical for the proliferative
response to mitogens or antigens [59–62]. Our experiments
demonstrate that by supplementing the GSH precursor,
NAC, ATCs can be protected from apoptosis at low cell
density, suggesting that the GSH peroxidase antioxidant
system may play an important role in ATC survival.
Other interventions that reduce intracellular ROS were
also effective in reversing the effect of low cell density to
inhibit T cell proliferation and survival. These included the
supplementation of cultures with purified catalase, which
detoxifies H2O2, and addition of high concentrations of
serum albumin, which contributes reducing cysteines that
can scavenge oxygen radicals.
One of the striking features of human serum albumin
is the presence of 34 cysteine residues forming 17 disulfide
bonds, and one free thiol at the Cys-34 position [63]. One-
third of the albumin molecules form mixed disulfides with
either GSH or half-cystine. The remaining sulfhydryl group
of the Cys-34 residue of albumin constitutes the major
extracellular source of reactive free thiol [64]. In this context,
it has been suggested that albumin constitutes an important
extracellular antioxidant in plasma [43]. The role of albumin
as an ROS scavenger has been confirmed in cell-free systems
with a wide variety of oxidative species, including HOCl,
H2O2, •OH, carbon radicals, and peroxynitrite [22, 65, 66],
as well as in intact cell systems such as macrophages and
renal tubular epithelium [42]. However, the mechanism by
which albumin exerts its antioxidant effects is most likely
multifactorial [42]. It is possible that the free sulfhydryl
group of albumin enables it to act not only as an antioxidant
but also as a reducing agent via modulation of cellular GSH
levels [44]. GSH in turn affects a wide variety of cell proteins,
the function of which is dependent on redox state, such as the
N-methyl-D-aspartic acid receptor, the DNA binding protein
activator protein-1, and NF-κB [67, 68].
Albumin has been an essential component of non-
serum culture mediums for expansion of T cells for clinical
applications. We explored the antioxidant role of albumin in
cell density-related death of ATCs. Concentration-dependent
reduction of intracellular ROS in ATCs cultured at low cell
density suggests that albumin reacted as an antioxidant to
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Figure 7: Improved activation with CD28 costimulation at low cell
density is accompanied by higher autocrine catalase secretion. Slot
blot of culture media from unactivated (lane 1), anti-CD3 antibody
(lane 2) and anti-CD3 antibody plus anti-CD28 antibody (lane 3)
activated PBMCs at 1 × 105/mL at 24 and 48 hours probed with
anticatalase antibody.
scavenge ROS. Compared to antioxidants catalase and NAC,
however, the effectiveness of albumin in reducing ROS is not
as strong, compatible with its action via these other indirect
mechanisms to rescue ATCs from apoptosis. The mechanism
of albumin’s action was not investigated further.
Interestingly, elevated intracellular albumin was detected
in ATCs cultured at low cell density, implicating increased
endocytosis under this condition, possibly in response to
elevated intracellular ROS. Albumin is bound on the surface
of lymphoid cells of all mammalian species tested [69], but its
function is relatively unknown. ATCs express albumin bind-
ing proteins and the binding of serum albumin increased
considerably upon blastic transformation [70]. Albumin
is endocytosed and the internalized albumin is detected
in peroxidase-conjugated form in lysosome-like bodies by
ultrastructural cytochemistry. Pulse-chase experiments show
that internalized albumin is finally released mainly in a
degraded form from the cells [70]. Whether increased
endocytosis of albumin under low-density conditions is an
adaptive response to elevated intracellular ROS to import
further reducing species into the cell is uncertain and was
not investigated further.
It is likely that those nontoxic antioxidants such
as sodium pyruvate [71], β-mercaptoethanol [72], DL-
penicillamine and thiolactate that exhibit protective effects
against ROS may have the same effect to protect ATCs from
apoptosis at low cell density. Whether these agents are useful
in the maintenance and growth of ATCs remains to be
determined.
4.4. Autocrine Catalase Protects ATCs from Apoptosis. Among
the naturally occurring variables examined, only one corre-
lated with the reversal of high levels of ROS under conditions
of high ATC cell density: the accumulation of secreted
catalase that raised extracellular levels of this potent anti-
oxidant enzyme. This extends studies of cultured leukemic T
and B cells [4, 5] suggesting that autocrine catalase functions
as a cytoprotective antioxidant in protecting cells at high
cell density from apoptosis. Furthermore, our results and
others’ indicate that this factor is not cell-type restricted and
is compatible with the observation that so-called “feeder”
cells of various origins can function to support T cells under
single-cell cloning conditions. We may infer that secretion
of catalase to suppress intracellular oxidative stress is a key
component of the supportive role of feeder cells.
How catalase is released from the cells is unclear. Catalase
lacks a leader sequence and cannot therefore be secreted by
the classic endoplasmic reticulum-Golgi secretory pathway
[73]. It is suggested that, like some cytokines, catalase may be
secreted via a leaderless secretory pathway [5]. It is unlikely
that the appearance of catalase in the medium derives from
dying cells. First, at high cell density, ATCs only begin to
die at late stages of expansion (after 3-4 weeks). The CM we
collected are from ATCs cultured at early stage of expansion
(2 weeks) with good viability. Second, we have shown that
CM from other cell lines that have very limited cell death can
also prevent ATC apoptosis.
It was noted that the endogenous cellular catalase was
similar in quantity to that secreted by the cells in 24 hours.
Whether the intracellular enzyme is in a compartment that
is functional or inactive is not addressed by these studies.
However, it is clear that cellular catalase is not a substitute
for the secreted component for maintaining cellular health;
otherwise, the cell concentration effects would not be
observed and CM would not rescue lower ATC densities from
apoptosis.
Finally, the quantities of catalase in the CM (6–
12 units/mL) (Figure 6(a)) corresponded closely to levels
of purified catalase (∼10 units/mL) that provide maximum
control of ROS and high ATC viability (Figure 4(b)).
Regarding how extracellular catalase activity might reg-
ulate intracellular oxidative stress, it is suggested that the
extracellular decomposition of H2O2 may create a concentra-
tion gradient favoring the diffusion of H2O2 out of the cells
[5].
A final speculation is warranted on the relevance of these
findings to the in vivo setting. The autocrine of catalase by
T cells may be an important factor for their proliferation.
At the time of activation, ATCs are at the highest level for
ROS generation and most vulnerable to oxidative cell death
[29]. At sites of high cellular density and low fluid efflux,
such as lymph node paracortex, catalase could be expected
to accumulate to high levels and support ATCs viability
and proliferation. On the other hand, ATCs trafficking
through the peripheral circulation will be dependent upon
blood/tissue levels of ROS and tissue secretion of catalase, as
well as serum albumin.
Another question remains to be answered is that the
elevated ROS in ATCs and an increased rate of their death
at low cell density may be a result of or partly related
to excessive oxygen concentration in the growth medium
cultivating in traditional incubators in comparison with
oxygen concentration in the blood. Nevertheless, our studies
clearly indicate that it is important to keep an antioxidant
environment for optimized expansion of T cells in vitro.
In conclusion, the present study examined the role of cell
density in T cell expansion in vitro. Several conclusions are
drawn from this work. First, we confirm that cell density
plays a critical role in T cell activation and ATC proliferation.
Resting T cells were activated to expand at high cell density
but failed to be activated at low cell density. ATCs grew
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rapidly at high cell density but underwent apoptosis at low
cell density in culture. Second, apoptosis of ATCs cultured
at low cell density correlated with elevated intracellular ROS
levels and was reversed by antioxidants NAC, catalase, and
albumin, indicating that the apoptosis of ATCs at low cell
density was mediated by ROS. Third, the increased survival
of ATCs at high cell density was due to non-IL-2 factor(s)
secreted by ATCs and non-ATCs alike. Fourth, autocrine
catalase was demonstrated to be the key survival factor
regulating ATC survival at high density by suppressing intra-
cellular ROS. Fifth, CD28 costimulation that improves T cell
activation at lower cell density is accompanied by enhanced
autocrine catalase secretion. Our findings highlight the
importance of cell density in T cell activation, proliferation,
survival, and apoptosis and suggest that it is critical to
maintain T cells at high cell density for the successful
expansion of T cells ex vivo for adoptive immunotherapy.
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